NCT05638828

A Study of RD14-01 in Patients With Advanced Solid Tumors

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Shen Lin · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and tolerability of RD14-01, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ advanced solid tumors.

Detailed description

This single-arm, open-label, dose-escalation and dose-expansion study will evaluate the safety and tolerability of RD14-01, ROR1-targeting CAR T cells, in adults with ROR1+ advanced solid tumors. The dose-escalation phase will investigate 3 dose levels to the. The dose-expansion phase will enroll .

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	RD14-01 Cell injection	RD14-01 Cell injection

Timeline

• Start date: 2022-12-01
• Primary completion: 2023-12-01
• Completion: 2024-12-01
• First posted: 2022-12-06
• Last updated: 2022-12-06